| scholarly article | Q13442814 |
| P50 | author | Susan M. Ramin | Q110252023 |
| P2093 | author name string | Wei Wang | |
| Yang Xia | |||
| Yujin Zhang | |||
| Rodney E Kellems | |||
| Roxanna A Irani | |||
| Sean C Blackwell | |||
| Lijian Tao | |||
| P2860 | cites work | Angiotensin receptors, autoimmunity, and preeclampsia | Q24605647 |
| Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models | Q28187934 | ||
| Complement. First of two parts | Q28210663 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Complement C3 activation is required for antiphospholipid antibody-induced fetal loss | Q33340713 | ||
| The spectrum of complement alternative pathway-mediated diseases | Q33380274 | ||
| Advances in understanding of pathogenesis of aHUS and HELLP. | Q33380684 | ||
| The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia | Q33591058 | ||
| Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia | Q33748650 | ||
| Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | Q33748680 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Complement fragments C3a and C5a: the salt and pepper of the immune response | Q34100792 | ||
| Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy | Q34182166 | ||
| C3aR inhibition reduces neurodegeneration in experimental lupus | Q34187724 | ||
| Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction | Q35576417 | ||
| Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
| Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice | Q35683468 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Receptor-activating autoantibodies and disease: preeclampsia and beyond | Q35707881 | ||
| Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia | Q35715914 | ||
| Renin angiotensin signaling in normal pregnancy and preeclampsia | Q35743816 | ||
| Preeclampsia and the systemic inflammatory response | Q35941015 | ||
| Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling | Q36050771 | ||
| The complement system in the pathophysiology of pregnancy | Q36197301 | ||
| Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction | Q36228832 | ||
| Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation | Q36468176 | ||
| Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats | Q36683260 | ||
| The role of the immune system in preeclampsia | Q36791219 | ||
| The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro | Q36975531 | ||
| Complement activation fragment Bb in early pregnancy and spontaneous preterm birth | Q36980611 | ||
| The functional role of the renin-angiotensin system in pregnancy and preeclampsia | Q37039872 | ||
| Complement activation and inhibition: a delicate balance. | Q37368654 | ||
| Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin | Q37430921 | ||
| Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes | Q37607702 | ||
| Complement activation in animal and human pregnancies as a model for immunological recognition | Q37877900 | ||
| Progress toward identifying potential markers for preeclampsia: role of agonistic autoantibody to the angiotensin II type I receptor | Q42701351 | ||
| C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage | Q43064545 | ||
| Effect of the C3a-receptor antagonist SB 290157 on anti-OVA polyclonal antibody-induced arthritis | Q43201779 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss | Q45681850 | ||
| Role of complement component C1q in the onset of preeclampsia in mice | Q46326820 | ||
| Targeted inhibition of complement activation prevents features of preeclampsia in mice | Q46329692 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Complement activation in angiotensin II-induced organ damage | Q46658434 | ||
| Complement 3 is involved in the synthetic phenotype and exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats | Q47622329 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. | Q54782424 | ||
| Local synthesis of complement component C3 regulates acute renal transplant rejection | Q57369617 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Activation of the complement system in normal pregnancy and preeclampsia | Q83021096 | ||
| Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension | Q83799951 | ||
| Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury | Q84372476 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| autoantibody | Q785022 | ||
| P304 | page(s) | 712-721 | |
| P577 | publication date | 2012-08-06 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia | |
| P478 | volume | 60 |
| Q38118625 | Activating autoantibodies and cardiovascular disease |
| Q38082526 | Adaptive immune responses during pregnancy |
| Q47546360 | Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q37699015 | Characterization of antibody specificities associated with preeclampsia |
| Q35738052 | Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia |
| Q46301263 | Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. |
| Q36236265 | Complement Split Products in Amniotic Fluid in Pregnancies Subsequently Developing Early-Onset Preeclampsia |
| Q30409861 | Complement activation is critical for placental ischemia-induced hypertension in the rat. |
| Q48164014 | Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies |
| Q35587280 | Complement factor B activation in patients with preeclampsia. |
| Q53717170 | Correlations between complement system's activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia. |
| Q34360684 | Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats |
| Q89495124 | Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia? |
| Q51614096 | Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. |
| Q92504562 | FOXD1 mutations are related to repeated implantation failure, intra-uterine growth restriction and preeclampsia |
| Q38525974 | From Glomerular Endothelium to Podocyte Pathobiology in Preeclampsia: a Paradigm Shift |
| Q47550799 | Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father |
| Q37605722 | Increased risk of systemic lupus erythematosus in pregnancy-induced hypertension: A nationwide population-based retrospective cohort study |
| Q64058094 | Low-dose aspirin protective effects are correlated with deregulation of HNF factor expression in the preeclamptic placentas from mice and humans |
| Q27303128 | Neutrophil Depletion Attenuates Placental Ischemia-Induced Hypertension in the Rat |
| Q35864583 | Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency |
| Q33765975 | Relationship between maternal immunological response during pregnancy and onset of preeclampsia |
| Q41653771 | Role of IgM and angiotensin II Type I receptor autoantibodies in local complement activation in placental ischemia-induced hypertension in the rat. |
| Q58081547 | Sialic acid is a critical fetal defense against maternal complement attack |
| Q47889401 | The Complement System and Preeclampsia |
| Q26863600 | The complement system and adverse pregnancy outcomes |
| Q54301416 | Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. |
Search more.